Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9281MR)

This product GTTS-WQ9281MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9281MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12071MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ13315MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ3242MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ARGX-113
GTTS-WQ15444MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ11830MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ12877MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ14192MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ8573MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW